NEOG
Neogen Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +0.2% · net new positions -6.7% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 90.75K | $1.06M | n/a | −1 |
| Q2 2026 | 99 | -2 | 145.67M | $1.31B | +8 | −11 |
| Q1 2026 | 105 | +4 | 149.62M | $1.39B | +10 | −7 |
| Q4 2025 | 101 | +1 | 145.41M | $1.02B | +3 | −1 |
| Q3 2025 | 15 | 0 | 86.70M | $495.04M | +1 | −2 |
| Q2 2025 | 13 | +1 | 84.31M | $402.96M | +2 | −1 |
| Q1 2025 | 9 | 0 | 40.38M | $350.08M | +1 | −1 |
| Q4 2024 | 9 | -2 | 40.94M | $497.00M | n/a | −2 |
| Q3 2024 | 10 | 0 | 36.89M | $620.15M | n/a | n/a |
| Q2 2024 | 10 | n/a | 39.27M | $613.84M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 32.02M | +4.6% | $182.81M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passive) | 23.96M | +1.6% | $136.83M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 8.75M | +1.8% | $49.97M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 5.87M | n/a | $33.51M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 5 | Geode Capital Management ✦ (passive) | 5.38M | +4.6% | $30.73M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | JPMorgan Chase ✦ | 3.36M | n/a | $19.19M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 7 | D. E. Shaw & Co. ✦ | 3.20M | +43.4% | $18.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Goldman Sachs Group ✦ | 2.04M | n/a | $11.65M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 9 | Citadel Advisors ✦ | 865.55K | -68.6% | $4.94M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 10 | Bridgewater Associates ✦ | 584.79K | New | $3.34M | 0.0% | New | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 236.11K | +2.8% | $1.35M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 12 | T. Rowe Price ✦ | 197.62K | +11.0% | $1.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Marshall Wace ✦ | 107.70K | -80.2% | $614,967 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 14 | GAMCO Investors ✦ | 100.50K | +17.9% | $573,855 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 27.32K | -17.8% | $155,980 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $3.34M | 0.0% |
Exited
| Norges Bank | $43.39M | was 0.0% |
| Millennium Management | $6.04M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 307 holders, 232.63M shares, $1.97B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · CEO · 505 sh @ 11.95 · $6,035
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology